A review on liquid chromatographic methods for the bioanalysis of atorvastatin

Karan Wadhwa and A. C. Rana

Abstract

Background: The unsatisfied clinical need has encouraged the development and validation of bioanalytical procedures for the quantification of drugs in biological samples because the monitoring of drug concentrations helps in personalizing the patient’s pharmacotherapy, assessing the adherence to therapy, and is also extensively useful for pharmacokinetics and drug-drug interactions studies.

Main Body: The present review aimed to provide insightful information about the various liquid chromatographic methods developed till 2019 for the analysis and quantification of atorvastatin, its metabolites, and co-administered drugs in the various biological matrices like the serum, plasma, and urine with special emphasis on sample preparation techniques applied before chromatographic analysis along with different chromatographic conditions and their validation data. A total of 88 published papers that have used liquid chromatography techniques to quantify atorvastatin in biological fluids are included in the study. Out of the total reported liquid chromatographic methods, 34% used UV spectrophotometer as a detector, and 55% used MS/MS as a detector. Whereas 38% of them used protein precipitation procedure, 33% applied liquid-liquid extraction approach, and 12% employed solid-phase extraction technique for sample preparation.

Conclusion: In the last decade, numerous bioanalytical procedures have been developed for the quantification of atorvastatin in different biological samples using liquid chromatographic techniques. Moreover, advancement in technology developed several new and advanced sample preparation approaches like dispersive liquid-liquid extraction, microextraction by packed sorbent, which have high recovery rates than conventional procedures. Thus, the summarized review may be consulted as an informative tool to support the optimization of new bioanalytical methods for the quantification of atorvastatin.

Keywords: Atorvastatin, Biological fluids, Bioanalytical techniques, Liquid chromatography, Sample preparation

Background

Statins (HMG CoA reductase inhibitors) are considered as the drug of choice for the treatment of hypercholesterolemia because of their extremely beneficial effect in reducing total cholesterol and low-density lipoprotein cholesterol levels in the human body [1]. Statins competitively inhibit the HMG-CoA reductase which further depletes the intracellular supply of cholesterol [2]. Atorvastatin (AT) (Fig. 1) is one of the oldest and major drug under the class of statins, which is chemically (3R,5R)-7-2-(4-Fluorophenyl)-3-phenyl-4-(phenyl arbamoyl)-5-propan-2-ylpyrrol-1-yl-3,5-dihydroxyheptanoic acid [3] and shows the highest low-density lipoprotein-cholesterol lowering efficacy in human at a maximum daily dose of 80 mg. With a molecular formula of C_{33}H_{15}FN_{2}O_{5} and a molecular weight of 558.064 g mol^{-1}, AT exists in two different forms, one is open-structured hydroxyl acid while another one is ring-structural lactone which degrades in both high alkaline and low acidic conditions [4]. AT has a significantly longer plasma half-life of 18–24 h compared to other statins [5]. AT is administered in its active acid form which afterward metabolized in its two active hydroxyl metabolites, i.e., ortho-hydroxy...
atorvastatin (o-OH AT) and para-hydroxy atorvastatin (p-OH AT) and three inactive lactone metabolites [6]. Runny nose, sneezing, and coughing are the most common side effects of AT whereas muscle problems, liver problems, loss of appetite, and upper stomach pain are certain serious side effects of AT [7]. AT is also clinically used to reduce the risk of stroke [8]; myocardial infarction [9], which further reduces the risk for angina [10]; and revascularization procedures [11]. Although plasma drug monitoring is not crucial for the AT, an increasing number of patients taking AT have drawn the attention of healthcare professionals for mandatory monitoring of plasma concentration in various conditions. Moreover, monitoring the plasma concentrations of AT helps personalize the patient’s pharmacotherapy and to assess the adherence to therapy. Since AT is also co-administered with many other drugs as polypharmacy therapy, the bioanalytical assays are also extensively used for its pharmacokinetics and drug-drug interactions’ studies. Thus, the unsatisfied clinical need has encouraged the development and validation of several liquid chromatography methods as bioanalytical procedures for the determination of AT in body fluids with high accuracy, precision, and better reproducibility. The present review encapsulates all reported liquid chromatography-based bioanalytical procedures available in the literature that are used for the quantification of AT alone, with its metabolites and with co-administered drugs in different biological samples. Also, a succinct tabular outline of the bioanalytical procedures has been included in the review which consists of chromatographic conditions, sample preparation strategies, validation data, etc.

**Main text**

Indeed, the best approach for the accurate analysis of drug concentration in biological samples is the use of high-resolution liquid chromatographic techniques such as HPLC and UPLC coupled with UV spectrophotometer or MS/MS detectors. Liquid chromatography techniques are not only considered as an important tool to support the therapeutic drug monitoring of drugs in the biological fluids but also during quality control of pharmaceutical formulations as well as during non-clinical and clinical drug development. From 1998 to 2019, different liquid chromatographic procedures to analyze AT in biological fluids were developed, validated, and applied in pharmacokinetic studies and therapeutic drug monitoring. Out of the total reported liquid chromatographic methods, 34% used UV spectrophotometer as a detector, and 55% used MS/MS as a detector.

**Analysis using HPLC**

HPLC is the preferable method for the analysis of drugs and currently the widest accepted method for separation technique. Table 1 [12–51] enlist the various HPLC methods coupled with UV, DAD, and PDA detectors used to detect AT and co-administered drugs in biological fluids. Usually, the reverse phase HPLC method
| Analyte(s)                           | Biological matrix | Sample preparation | Mode of elution; mobile phase                        | Stationary phase                                      | Flow rate (mL min⁻¹) | Detection | R_t (min) | Calibration range | LOD | LOQ | % Recovery | Ref. |
|-------------------------------------|-------------------|--------------------|------------------------------------------------------|-------------------------------------------------------|----------------------|-----------|-----------|-------------------|-----|-----|-----------|------|
| AT and curcumin Mouse plasma PP     | Isocratic elution; ACNMeOHt2% (v/v) AcA (37.5%2.5%, v/v/v) | Purospher STAR RP18 endcapped column (55 x 4 mm, 3 μm) | 1.0 DAD247 nm | 600-50,000 ng mL⁻¹ = ng mL⁻¹ | 66.70 | ---       | 91.28%   | [12]          |     |     |          |     |
| Rosuvastatin, gemfibrozil, and AT   | Human plasma MD-SPE-SSME | Isocratic elution; ACNsodium phosphate buffer (pH 3, 0.05 M) (59:41, v/v) | C18 column (250 x 4.6 mm, 5 μm) | 1.0 UV230 nm | ≈9.0 | 30-2000 ng mL⁻¹ = ng mL⁻¹ | 10.00 | 9.70 | 98.75%   | [13] |
| AT and clopidogrel Human plasma PP  | Isocratic elution; KH₂PO₄ buffer (pH 2.5); ACN (50:50, v/v/v) | C8 column (250 x 4.6 mm, 5 μm) | 1.3 PDA243 nm | 10-50 μg mL⁻¹ | 9.70 | ---       | 98.75%   | [14]          |     |     | 97.80%   | [14] |
| AT, clopidogrel and Aspirin Rat plasma PP | Gradient elution; A = Dibasic phosphate buffer (pH 30.10 mM), B = ACN | Beta-basic C18 column (250 x 4.6 mm, 5 μm). | 1.0 UV232 nm | 10-10,000 ng mL⁻¹ | 10.00 | ---       | 92.85%   | [15]          |     |     | 92.85%   | [15] |
| AT Human plasma DLLME-SFO           | Isocratic elution; MeOH,water (70:30,v/v) (pH=3.0 with Sodium phosphate buffer) | Shim-pack CLC-C18 column (150 x 4.6 mm, 5 μm). | 1.5 UV | 0.2-6000 μg mL⁻¹ | 0.07 | ---       | 9880-11380% | [16]          |     |     |        |      |
| AT and pioglitazone Rat plasma LLE  | Isocratic elution; MeOH:ACN:AFL (pH 3.5; 1 mM) (48:19:33 v/v/v) | Gemini C18 column (250 x 4.6 mm, 5 μm) | 1.0 DAD260 nm | 6-300 ng mL⁻¹ | 3.00 | 6.00 | 74.03%   | [17]          |     |     | 99.50%   | [18] |
| AT Human serum SALLE                | Isocratic elution, AA bufferACN (50:50, v/v) (pH=3.0 with o-phosphoric acid) | Symmetric C18 column (250 x 4.6 mm, 5 μm) | 1.0 UV246 nm | --- | 1-10,000 ng mL⁻¹ | 0.50 | ---       | 99.50%   | [18]          |     |     | 99.50%   | [18] |
| AT micro-emulsions Rat plasma PP    | Isocratic elution; MeOH,water (70:30, v/v) (0.05% glacial AcA) | C18 column (250 x 4.6 mm, 5 μm) | 1.0 UV248 nm | 100-50,000 ng mL⁻¹ ≥ 0.9854 | 2000 | 50.00 | 91.16%   | [19]          |     |     |          |      |
| Analyte(s) | Biological matrix | Sample preparation | Mode of elution; mobile phase | Stationary phase | Flow rate (mL min\(^{-1}\)) | Detection | Retention (min) | Calibration range | LOD (ng mL\(^{-1}\)) | LOQ (ng mL\(^{-1}\)) | % Recovery | Ref. |
|------------|-------------------|--------------------|-------------------------------|-----------------|-----------------------------|-----------|----------------|-------------------|----------------|----------------|------------|------|
| AT, rosuvastatin | Rat plasma | LLE | Isocratic elution; MeOH: H\(_2\)O: water (68:32, v:v) (pH 3.0) | BDS Hypersil C18 column (250 × 4.6 mm, 5 μm) | 1.0 | UV241 nm | 11.3 | 20–200 ng mL\(^{-1}\); \(R_s^2 = 0.9920\) | 1.30 ng mL\(^{-1}\); 10.30 ng mL\(^{-1}\) | 96.48% | [20] |
| AT | Human serum | LLE | Isocratic elution; 10% MeOH in sodium phosphate buffer (pH 3.5; 0.05 M with o-phosphoric acid); MeOH (45:57, v/v) | Ascentis C18 column (250 × 46 mm, 5 μm) | 1.2 | UV247 nm | 19.8 | 3–150 ng mL\(^{-1}\); \(R_s^2 = 0.9990\) | 1.20 ng mL\(^{-1}\); 3.00 ng mL\(^{-1}\) | 85.10% | [21] |
| Pioglitazone, glibenclamide, and AT | Human serum | PP | Isocratic elution; MeOH: H\(_2\)O: 90:10: v/v (pH 3.50 with o-phosphoric acid) | Purospher Star RP18 endcapped column (250 × 46 mm, 5 μm) | 1.0 | UV235 nm | 3.6 | 5–50 μg mL\(^{-1}\); \(R_s^2 = 0.9989\) | 0.60 μg mL\(^{-1}\); 1.90 μg mL\(^{-1}\) | 98.80–104.3% | [22] |
| AT, Losartan, atenolol, and aspirin | Plasma | PP | Isocratic elution; ACN:KH\(_2\)PO\(_4\) (pH 3.4; 0.02 M) (70:30, v/v) | HiQ Sil C18 HS column (250 × 46 mm, 5 μm) | 1.0 | UV236 nm | 5.2 | 25–150 ng mL\(^{-1}\); \(R_s^2 = 0.9997\) | --- | 25.00 ng mL\(^{-1}\); 99.46% | [23] |
| AT and simvastatin | Human plasma | SPE, DLLME | Isocratic elution; AA solution (pH 3.5; 0.02 M) + ACN (25:75, v/v) | Luna C18 column (150 × 46 mm, 5 μm) | 0.7 | DAD254 nm | --- | 45–900 ng mL\(^{-1}\); \(R_s^2 = 0.9990\) | 25.00 ng mL\(^{-1}\); 75.00 ng mL\(^{-1}\); 90.00%, 83.00% | [24] |
| AT | Human plasma | PP | Isocratic elution; MeOH:ACN:Sodium phosphate buffer (pH 4.5; 0.01 M) (40:30:30, v/v/v) | Shim-Pak C18 column (250 × 46 mm, 5 μm) | 1.0 | UV247 nm | --- | 5–160 ng mL\(^{-1}\); \(R_s^2 = 0.9990\) | 7.80 ng mL\(^{-1}\); 22.90 ng mL\(^{-1}\); 98.70% | [25] |
| AT and fenofibrate | Rabbit plasma | PP | Isocratic elution; KH\(_2\)PO\(_4\):ACN:28:72, v/v (pH 4.1) | Capcell Pak C8 DDS5 column (250 × 46 mm, 5 μm) | 1.0 | UV260 nm | 4.2 | 1–40 μg mL\(^{-1}\); \(R_s^2 = 0.9993\) | 0.05 μg mL\(^{-1}\); 0.20 μg mL\(^{-1}\); 9704% | [26] |
| AT and rosuvastatin | Human serum | LLE | Isocratic elution; MeOH: H\(_2\)O: water (68:32, v/v) (pH 3.0) | Brownlee analytical C18 column (150 × 4.6 mm, 5 μm) | 1.5 | UV241 nm | 6 | 3–384 ng mL\(^{-1}\); \(R_s^2 = 0.9990\) | 1.00 ng mL\(^{-1}\); 3.00 ng mL\(^{-1}\); 98.20% | [27] |
| Lisinopril, AT, pravastatin, and rosuvastatin | Human Serum | PP | Isocratic elution; MeOH: H\(_2\)O: ACN (80:17.5:2.5, v/v/v) (pH 3.0) | Purospher STAR C18 column (250 × 4.6 mm, 5 μm) | 1.0 | UV225 nm | 8.3 | 625–25,000 ng mL\(^{-1}\); \(R_s^2 = 0.9994\) | 1.30 ng mL\(^{-1}\); 4.10 ng mL\(^{-1}\); 100.86% | [28] |
| Fluvastatin, pravastatin, and AT | Human plasma | PP | Isocratic elution; ACN:KH\(_2\)PO\(_4\):60:40, v/v (pH 3.5 by o-phosphoric acid) | ZORBAX Extend-C18 column (150 × 4.6 mm, 5 μm) | 1 | UV210 nm | 2.4 | 5–200 μg mL\(^{-1}\); \(R_s^2 = 0.9990\) | 2.5 μg mL\(^{-1}\); 4.00 μg mL\(^{-1}\); 99.80% | [29] |
| AT and gemfibrozil | Human plasma | PP | Isocratic elution; AA buffer (pH 5.0; 0.1 M + ACN (45:55, v/v) | C18 column (250 × 4.6 mm, 5 μm) | 1.0 | PDA240 nm | 3.4 | 1–20 μg mL\(^{-1}\); \(R_s^2 = 0.9997\) | 3000 ng mL\(^{-1}\); 1.0 ng mL\(^{-1}\); 93.54% | [30] |
| AT | Human plasma | LLLME | Isocratic elution; ACN:0.1% AcA (70:30, v/v) | ODS-3 column (150 × 46 mm, 5 μm) | 1.0 | UV246 nm | 2.7 | 1–500 ng mL\(^{-1}\); \(R_s^2 = 0.9997\) | 0.40 ng mL\(^{-1}\); 1.00 ng mL\(^{-1}\); 2290% | [31] |
| AT | Beagle dog plasma | PP | Isocratic elution; ACN:AA buffer (pH 4; 0.1 M) (65:35, v/v) | Kromasil C8 column (150 × 46 mm, 5 mm) | 1.0 | UV270 nm | 6.6 | 50–2500 ng mL\(^{-1}\); \(R_s^2 = 0.9995\) | 8.00 ng mL\(^{-1}\); 25.00 ng mL\(^{-1}\); 91.30% | [32] |
| Analyte(s) | Biological matrix | Sample preparation | Mode of elution; mobile phase | Stationary phase | Flow rate (mL min⁻¹) | Detection | R_s (min) | Calibration range | LOD | LOQ | % Recovery | Ref. |
|-----------|------------------|--------------------|-----------------------------|----------------|---------------------|----------|----------|-----------------|-----|-----|----------|-----|
| AT        | Human plasma     | PP                 | Isocratic elution; NaH₂PO₄ (0.01 M) : ACN (60:40, v/v) (pH 5.5) | Nucleosil-100 C8 column (125 × 4 mm, 5 μm) | 1.5 | UV245 nm | 3.6 | 20–800 ng mL⁻¹ | 1.00 ng mL⁻¹ | --- | 100.20% | [33] |
| AT        | Human serum      | LLE                | Isocratic elution; sodium phosphate buffer (pH 4.05) : MeOH (33:67, v/v) | Shim-pack CLC-C18 column (100 × 4 mm, 5 μm) | 2.5 | UV247 nm | 3.4 | 4–256 ng mL⁻¹ | 1.00 ng mL⁻¹ | 4.00 ng mL⁻¹ | 95.00 ± 400% | [34] |
| Metformin, amlodipine, glibenclamide, and AT | Human plasma | PP | Gradient elution; A = 0.1% o-phosphoric acid (pH 3.0), B = ACN | Novapack Phenyl column (150 × 4.6 mm, 5 μm) | --- | UV227 nm | 11.8 | 100–5000 ng mL⁻¹ | --- | 1.00 ng mL⁻¹ | 91.19% | [35] |
| Metformin, amlodipine, glibenclamide, and AT | Human plasma | DLE | Isocratic elution; ACN:MeOH:water (45:45:10, v/v/v) | RP C18 column (150 × 4.6 mm, 5 mm) | 1.0 | UV240 nm | 1.9 | 500–86,000 ng mL⁻¹ | 8.40 ng mL⁻¹ | 17.90 ng mL⁻¹ | 98.90% | [36] |
| AT        | Human plasma     | PP                 | Isocratic elution; ACN:MeOH:water (45:45:10, v/v/v) | C18 column (250 × 4.6 mm, 5 μm) | 1.0 | Fluorimetric282 nm, 400 nm | 4.4 | 30–120 ng mL⁻¹ | 1.00 ng mL⁻¹ | 30.00 ng mL⁻¹ | 101.35% | [37] |
| AT and valsartan | Human serum | Solid based DLE | Isocratic elution; sodium phosphate buffer (pH 6.0) | Spherisorb C18 column (25 × 4.6 mm, 5 μm) | 0.7 | DAD210 nm | 8.0 | 10–5000 ng mL⁻¹ | 2.60 ng mL⁻¹ | 8.20 ng mL⁻¹ | 81.00% | [38] |
| AT        | Rat plasma       | PP                 | Isocratic elution; ACN:MeOH (50:40:10, v/v/v) | Knaier Vertex Plus C18 (250 × 4.6 mm, 5 μm) | 0.9 | UV240 nm | 9.1 | 10–12,000 ng mL⁻¹ | 0.70 ng mL⁻¹ | 2.20 ng mL⁻¹ | 102.48% | [39] |
| AT        | Human plasma     | DMSPE              | Isocratic elution; dibasic phosphate buffer (pH 3.0) | Beta-basic C18 column (100 × 4.6 mm, 5 μm) | 1.0 | UV240 nm | 12.1 | 0.05–10 μg mL⁻¹ | 0.9990 | --- | 92.80% | [40] |
| AT        | Human plasma     | DLE                | Gradient elution; A = sodium phosphate buffer (pH 2.6) : 10 mM, B = ACN, | BDS Hypersil C18 column (250 × 4.6 mm, 5 μm) | 1.0 | PDA220 nm | 10.9 | 5–2500 ng mL⁻¹ | 2.00 ng mL⁻¹ | 5.00 ng mL⁻¹ | 94.50% | [41] |
| AT        | Human plasma     | PP                 | Isocratic elution; KH₂PO₄ (pH 3.5) : 0.05 M adjusted with o-Phosphoric acid : ACN | X-Terra C8 column (150 × 4.6 mm, 3.5 μm) | 1.2 | PDA235 nm | 3.5 | 5–25 μg mL⁻¹ | 0.9940 | --- | 100.42% | [42] |
| AT        | Human plasma     | SPE                | Isocratic elution; MeOH:ACN:water (7:6:1, v/v/v) | Knauer C18 column (250 × 4.6 mm, 5 μm) | 1.0 | UV253 nm | --- | 0.3–2000 ng mL⁻¹ | 0.06 ng mL⁻¹ | 0.20 ng mL⁻¹ | 101.80% | [43] |
| AT        | Human plasma     | Ultrasound-assisted MSPE | Isocratic elution; ammonium dihydrogen phosphate buffer (pH 3.0) | Teknokrom C18 column (250 × 4.6 mm, 5 μm) | 1.5 | UV246 nm | 5.0 | 0.4–500 ng mL⁻¹ | 0.10 ng mL⁻¹ | --- | 94.58% | [44] |
| Analyte(s) | Biological matrix | Sample preparation | Mode of elution; mobile phase | Stationary phase | Flow rate (mL min$^{-1}$) | Detection | R$_t$ (min) | Calibration range | LOD | LOQ | % Recovery | Ref. |
|------------|-------------------|--------------------|-----------------------------|-----------------|-------------------------|-----------|-----------|------------------|-----|-----|------------|------|
| AT and glimepiride | Human serum | LLE | Isocratic elution; ACN: water (containing 1% v/v triethylamine) (55:45, v/v/v) (pH 5.6 with o-phosphoric acid) | Inertsil C18 column (250 x 46 mm, 5 μm) | 1.0 | UV230 nm | 6.9 | 1–1600 ng mL$^{-1}$ | --- | 1.00 ng mL$^{-1}$ | 94.83% | [45] |
| AT and Lercanidipine | Rat plasma | PP | Isocratic elution; ACN:AA buffer (pH 3.5; 0.1 M) (50:50, v/v) | Wakosil II C18 column (250 x 46 mm, 5 μm) | 1.2 | UV235 nm | 10.2 | 0.05–40 μg mL$^{-1}$ | --- | --- | 89.00-94.00% | [46] |
| AT and valsartan | Human serum | MD- SPE | Isocratic elution; MeOH:ACN: Sodium phosphate buffer (pH 3.0) (40:25:35, v/v/v) | Licrosorb RP-18 column (100 x 4.6 mm, 3.5 μm) | 1.0 | UV240 nm | --- | 10–2000 ng mL$^{-1}$ | 2.40 ng mL$^{-1}$ | 8.00 ng mL$^{-1}$ | 92.83% | [47] |
| AT | Rat plasma | PP | Isocratic elution; MeOH:water (70:30, v/v/v) (pH 5.5) | C18 column (250 mm x 46 mm, 5 μm) | --- | UV | 4.9 | 50–1000 ng mL$^{-1}$ | 100 ng mL$^{-1}$ | 15.0 ng mL$^{-1}$ | 93.55% | [48] |
| AT | Human serum | MD- SPE | Isocratic elution; ACN:water (45:55, v/v) | Licrosorb RP-18 column (100 x 4.6 mm, 3.5 μm) | 1.0 | DAD | --- | 1–1000 ng mL$^{-1}$ | 0.10 ng mL$^{-1}$ | 0.40 ng mL$^{-1}$ | 96.03% | [49] |
| Captopril, rosuvastatin, simvastatin, and AT | Human serum | PP | Isocratic elution; ACN:water (60:40, v/v) (pH 2.9 with phosphoric acid) | Purospher STAR C18 column (250 x 46 mm, 5 mm) | 1.5 | UV230 nm | ≈ 3.9 | 625–25,000 ng mL$^{-1}$ | 5.87 ng mL$^{-1}$ | 17.80 ng mL$^{-1}$ | 99.76% | [50] |
| Rosuvastatin, gemfibrozil, and AT | Human plasma | TAALLME-SFO | Isocratic elution; ACN:Sodium phosphate buffer (pH 3; 0.05 M) (61:39, v/v) | ODS III column (250 x 46 mm, 5 mm) | 1.0 | UV230 nm | --- | 2.5–3000 ng mL$^{-1}$ | 0.80 ng mL$^{-1}$ | --- | 101.00% | [51] |

*The pH of the mixed solvent system.*
has been used to quantify AT using C18 analytical columns because of the presence of pyrrole and phenyl as aromatic functional groups that make analysis suitable by the reverse phase method [52]. However, some published work has used the C8 column as the stationary phase. The mobile phase that has been used in the quantification of AT in biological matrices, primarily comprised of acetonitrile (ACN), methanol (MeOH), water, and different buffer solutions that have either isocratic or gradient elution with a flow rate of 1 mL min$^{-1}$. Retention of analyte in the analytical column hinge upon the pH of elution, so in reported bioanalytical assays, pH of the mobile phase has been maintained between 2 and 4 to make better retention of analyte in the analytical column and enhanced the resolution of the peak because these pH values are lesser than pKa value of AT and AT remain in unionized form for a longer time and interact more with the stationary phase [52]. The retention time ($R_t$) of AT reported in Table 1 variegates from 1.7 to 19.8 min, but in most of the developed HPLC methods, $R_t$ has ranged 2 to 5 min. The wavelength of UV detector used to detect AT has ranged from 210 to 270 nm, but commonly, 247 nm has been used as detection wavelength. Conversely, Tekkeli et al. quantify AT in human plasma using fluorimetric detection at excitation wavelength. Conversely, Tekkeli et al. quantify AT in human plasma using fluorimetric detection at excitation and an emission wavelength of 282 and 400 nm, respectively [37]. For the accuracy in quantification, diclofenac [20, 26, 31, 34] and ibuprofen [29, 39] have been often employed as internal standards in various developed HPLC methods to determine AT. Considering the validation of developed methods, all the developed methods have been validated as per ICH Q2 (R1) guidelines for system suitability, sensitivity, selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), and inter-day and intra-day accuracy and precision. LOD of the AT has been determined based using signal intensity to baseline noise ratio (S/N) of 3:1 by comparing test results from samples of a known concentration of analyte with the blank sample while LOQ determination has been based on signal intensity ten times more than baseline noise, i.e., $S/N = 10$. Least LOQ and LOD value of 0.2033 ng mL$^{-1}$ and 0.0608 ng mL$^{-1}$ respectively were observed in the method proposed by Dastkhvon et al. [43], whereas the method developed by Gholami and Ahmadi was highly sensitive with LOQ value of 0.38 ng mL$^{-1}$ and LOD value of 0.10 ng mL$^{-1}$ with linearity in concentration calibration range of 1 to 1000 ng mL$^{-1}$ and %RSD less than 4.2% [49].

**Analysis using LC-MS/MS and UPLC-MS/MS**

The liquid chromatography-based bioanalytical procedures using MS/MS detectors are listed in Table 2 [53–100]. On the other hand, few studies used UPLC-MS/MS method for the estimation of AT in the biological fluids and are also indexed in Table 2 [55, 56, 65, 71, 74, 81, 87, 91, 94, 95, 100]. Similar to HPLC-UV methods, C18 analytical columns have been extensively used in LC-MS/MS assay as a stationary phase because their long alky chain provides more efficient separation of nonpolar compounds in MS/MS detection [101], whereas a column packed with bridge ethyl hybrid (BEH) has been used in UPLC method as a stationary phase [71, 81, 87, 95] because of their high mechanical resistance [102]. Although MeOH, ACN, and water are used as mobile phases for quantification in LC-MS/MS, certain additives like formic acid (FA), ammonium acetate (AA), and acetic acid (AcA) have been added in the mobile phase to enhance ionization which further increases the sensitivity of the method. Isocratic elution has been predominantly preferred over gradient elution in the analysis of AT with an elution rate of 0.2–0.5 mL min$^{-1}$, $R_t$ has found to be quite small, ranged between 0.66 and 6.3 min. AT and its metabolites can be detected in both positive and negative ionization modes of MS, yet most of the published work has performed LC-MS/MS analyses of AT in positive ionization mode using electrospray ionization (ESI), but few reported studies used negative ions [54, 56, 58, 67, 80, 94] of AT for the analysis even though, polarity switching work has performed LC-MS/MS analyses of AT in positive ionization mode using electrospray ionization (ESI), but few reported studies used negative ions [54, 56, 58, 67, 80, 94] of AT for the analysis even though, polarity switching within run is required in ESI$^+$ mode [89]. On the other hand, the atomic pressure chemical ionization (APCI) technique has been used by Tabboub for ionization of AT in positive mode [64]. Figures 2 and 3 represent the product ion spectra of AT and metabolites in both ESI$^+$ and ESI$^-$ modes respectively. Interestingly, a study by Partani et al. concluded that analysis in ESI$^+$ mode gives quite low LOQ value because the negative ions enhance the selective detection and also improve the sensitivity of the method [67]. Principally, quantification of AT has been carried out using multiple reaction monitoring (MRM) transition with the precursor ion M+H$^+$ at m/z 559 Da and product ion at m/z 440 Da, while SRM transition has also been employed in numerous ESI$^+$ methods with transitions at m/z 559 $\rightarrow$ 440 [52, 65, 70, 81, 88, 89]. Importantly, Jang et al. utilized the MRM transition of m/z 559 $\rightarrow$ 250.2 for the detection of AT in the human urine samples [92]. Negative ions of AT have been analyzed at m/z 557.4 $\rightarrow$ 278.1 in the MRM transition [56, 58, 67] but in some ESI$^-$ mode quantification of AT has been carried out with product ion at m/z 397 [56, 60, 80] while AT was detected using MRM transition 557.0 $\rightarrow$ 453.0 in the bioanalytical method proposed by Xia et al. [94]. Interestingly, Varghese and Kochupappay Ravi [53] and Ma et al. [84] performed the analysis of AT using LC–ESI–MS in selected ion monitoring (SIM) mode at m/z 559. In most of the LC-MS/MS assays, either deuterium-labeled analogs of AT (d$_5$-AT) or structural analogs of AT such as rosuvastatin [53, 55, 58, 66, 86, 94], pitavastatin [66, 84], and pravastatin [70, 80] have been selected as internal standards to get most accurate results.
Table 2: Reported analytical method for the estimation of AT, its metabolites, and co-administered drugs in biological fluids using LC-MS/MS technique

| Analyte(s)                                      | Biological matrix | Sample preparation | Mode of elution; mobile phase | Stationary phase | Flow rate (mL min⁻¹) | Detection | R (min) | Calibration range | LOD (ng mL⁻¹) | LOQ (ng mL⁻¹) | % Recovery | Ref. |
|------------------------------------------------|-------------------|--------------------|-------------------------------|------------------|----------------------|-----------|--------|-------------------|--------------|--------------|------------|------|
| AT and telmisartan                             | Human plasma      | LLE                | Isocratic elution; AA (pH 4.0, 0.1% FA) MeOH (20:80, v/v) | Luna C18 (150 × 46 mm, 5 µm) | 0.4 | MS ESI+SIM559 | 3.8 | 1–35 ng mL⁻¹ | 0.9930 | 100 ng mL⁻¹ | 81.48% | [53] |
| AT, fluvastatin, simvastatin, pravastatin, rosvastatin, lovastatin, pitavastatin, and metabolites | Human plasma | LLE | Gradient elution; A = water containing 1% ACN, 0.1% FA, 2 mM AF, B = ACN containing 1% water, 0.1% FA, 2 mM AF | Hypersil Gold C18 column (100 × 2.1 mm, 1.9 µm) | 0.7 | HRES/MS/ESI+HESI+ SRM559 → 440 | 4.5 | 1–100 ng mL⁻¹ | 0.9994 | 100 ng mL⁻¹ | 87.93% | [54] |
| AT                                            | Human plasma      | LLE                | Gradient elution; A = 0.2% FA, B = ACN | Acquity UPLC BEH C18 column (100 × 2.1 mm, 1.7 µm) | 0.3 | MS/MS ESI−MRM559.05 → 440 | --- | --- | 0.2–100 ng mL⁻¹ | 0.9998 | --- | --- | [55] |
| AT, simvastatin, fluvastatin, fluvastatin, olmesartan, pitavastatin, rosuvastatin, pravastatin, and metabolites | Human serum | PP-MEPS | Gradient elution; A = ACN, B = AA (0.5 mM) | Acquity UPLC BEH C18 column (100 × 2.1 mm, 1.7 µm) | 0.3 | MS/MS ESI−SRM557.2 → 278.2 | 2.5 | 5–1000 ng mL⁻¹ | 0.999 | 1000 ng mL⁻¹ | 100 ng mL⁻¹ | [56] |
| AT, α-OH AT, p-OH AT, and AT Lactone          | Rat plasma        | SPE                | Gradient elution; A = ACN, B = 0.1% AcA | ZORBAX Eclipse C18 Analytical column (100 × 4.6 mm, 3.5 µm) | 0.4 | MS/MS ESI−MRM559.47 → 4403 | 4.5 | 0.1–20 ng mL⁻¹ | 0.9982 | 0.05 ng mL⁻¹ | 87.93% | [57] |
| AT, α-OH AT, and p-OH AT                      | Human plasma      | LLE                | Isocratic elution; 0.3% FA in water; 0.3% FA in ACN (50:50, v/v) | Purospher STAR RP 18 endcapped column (55 × 2 mm, 3 µm) | 0.5 | MS/MS ESI−SRM557.4 → 397 | 2.4 | 1.99–80.52 ng mL⁻¹ | 0.9954 | 204 ng mL⁻¹ | 82.87% | [58] |
| AT and amlodipine                             | Human plasma      | LLE                | Isocratic elution; ACNAA buffer (pH 30,10 mM (70:30, v/v) | ZORBAX XDB-C18 column (30 × 2.1 mm, 3.5 µm) | 0.15 | MS/MS ESI−MRM559.3 → 4402 | 3.8 | 0.2–20 ng mL⁻¹ | 0.9990 | 0.10 ng mL⁻¹ | 94.56% | [59] |
| AT, α-OH AT, and p-OH AT                      | Human plasma      | LLE                | Isocratic elution; ACN0.2% FA (65:35, v/v) | Luna C18 column, 100 × 4.6 mm, 5 µm | 0.6 | MS/MS ESI−SRM557.3 → 397.3 | 3.7 | 0.2–202 ng mL⁻¹ | 0.9969 | --- | 76.14% | [60] |
| Simvastatin, lovastatin, AT, and metabolites  | Human plasma      | PP                 | Gradient elution; A = Water, B = ACN (0.2% FA and 2 mM AF) | ZORBAX Extend C18 column (50 × 2.1 mm, 5 µm) | 0.4 | MS/MS ESI−MRM559.2 → 4402 | 8.4 | 0.1–100 nM2 ≥ | 0.9950 | --- | 102.08% | [61] |
| AT, α-OH AT, and p-OH AT                      | Human plasma      | SALLE              | Gradient elution; A = water (1%FA), B = ACN | Kinetex XB C18 column (50 × 2.1 mm, 2.6 µm) | 0.8 | MS/MS ESI−MRM559.3 → 4402 | 2.2 | 0.02–15 ng mL⁻¹ | 0.9986 | 0.02 ng mL⁻¹ | 87.93% | [62] |
| AT and olmesartan                             | Human plasma      | LLE                | Isocratic elution; ACNMeOH0.1% FA | Eclipse Plus C18 | 0.5 | MS/MS | 2.0 | 2–80 ng | 0.19 ng | 80.26% | [63] |
Table 2: Reported analytical method for the estimation of AT, its metabolites, and co-administered drugs in biological fluids using LC-MS/MS technique (Continued)

| Analyte(s) | Biological matrix | Sample preparation | Mode of elution; mobile phase | Stationary phase | Flow rate (mL min⁻¹) | Detection | Rᵣ (min) | Calibration range | LOD | LOQ | % Recovery | Ref. |
|------------|------------------|-------------------|-----------------------------|-----------------|---------------------|-----------------|--------|------------------|-----|-----|-----------|-----|
| AT and other cardio vascular drug | Human plasma | PP | Gradient elution; A = 0.1% (v/v) aqueous FA with 1.0 mM AF, B = 0.1% (v/v) FA with 1.0 mM AF in ACN | C18 column (50 x 46 mm, 5 μm) | 06 | MS/MS APCI MRM559.6 → 4403 | 5.5 | --- | --- | 7.20 | 90.50% | [64] |
| AT, metoprolol, amlodipine, pravastatin, rosuvastatin, and metabolites | Human plasma | PP | Gradient elution; A = water with 0.1% FA, B = ACN with 0.1% FA | Acquity UPLC CSH column (50 x 2.1 mm, 1.7 μm) | 05 | MS/MS ESI+SRM559 → 440 | 2.5 | 0.2–500 ng mL⁻¹ | 0.30 ng mL⁻¹ | --- | 80.00–103.00% | [65] |
| AT and ezetimibe | Human plasma | LLE | Isocratic elution; 0.2% FA in water:ACN (30:70, v/v) | Eclipse-plus C18 column (100 x 46 mm, 3.5 μm) | 06 | MS/MS ESI+ MRM559 → 440 | 2.7 | 20–3000 ng mL⁻¹ | 0.9998 | --- | 76.32% | [66] |
| AT, o-OH AT, and p-OH AT | Human plasma | SPE | Isocratic elution; 0.005% FA in water:ACN:MeOH (35:25:40, v/v/v) | Ascentis Express C18 column (75 x 4.6 mm, 2.7 μm) | 06 | MS/MS ESI+ MRM557.4 → 278.1 | 4.1 | 0.05–100.138 ng mL⁻¹ | 0.9991 | 0.05 ng mL⁻¹ | 77.40% | [67] |
| Glimepiride, metformin, and AT | Human plasma | PP | Isocratic elution; ACN:AA (pH 3.0; 10 mM) (60:40, v/v) | Altima HP C18 HL column (50 x 46 mm, 3 μm) | 1.1 | MS/MS ESI+MRM559.42 → 440 | 5.4 | 0.035–25 ng mL⁻¹ | 0.9966 | --- | 80.26% | [68] |
| Amlodipine, AT, o-OH AT, and p-OH AT | Human plasma | LLE | Isocratic elution; ACN: AA buffer (20 mM) (50:50, v/v) (0.3% FA mixed) | Cap-cellpak C1 (4 column (150 x 2 mm, 5 μm)) | 0.45 | MS/MS ESI+ MRM559.6 → 44025 | 1.5 | 1.5–150 ng mL⁻¹ | 0.9999 | 1.50 ng mL⁻¹ | 103.47% | [69] |
| Amlodipine, AT, o-OH AT, and p-OH AT | Human plasma | PP | Isocratic elution; water:MeOH (1:4:86, v/v) (pH 3.2 with TCA) | Synergy 4 μm polar-RP 80Å column (150 x 4.6 mm, 4 μm) | 05 | MS/MS ESI+ SRM559.09 → 44021 | 5.5 | 0.5–150 ng mL⁻¹ | 0.9999 | 1.50 ng mL⁻¹ | 103.47% | [70] |
| AT and ezetimibe | Human plasma | LLE | Gradient elution; A = 0.1% FA in water, B = ACN | Acquity UPLC BEH C18 column (50 x 2.1 mm, 1.7 μm) | 0.7 | MS/MS ESI+MRM559.5 → 4404 | 1.0 | 0.015–150.53 ng mL⁻¹ | 0.9900 | 1.50 ng mL⁻¹ | 96.72% | [71] |
| AT and aspirin | Human plasma | LLE | Isocratic elution; 0.2% AcA buffer; MeOH:ACN (30:70, v/v) | ZORBAX XDB Phenyl column (75 x 46 mm, 3.5 μm) | 0.8 | MS/MS ESI+ MRM559.2 → 440 | 5.5 | 0.050–250 ng mL⁻¹ | 0.9966 | 0.04 ng mL⁻¹ | 82.80% | [72] |
| AT and glimepiride | Human plasma | LLE | Isocratic elution; 0.1% FA:ACN (30:70, v/v) | ACE 5 C18 column (50 x 4.6 mm, 5 μm) | 0.5 | MS/MS ESI+ MRM559.42 → 4401 | 1.3 | 0.2–15.1 ng mL⁻¹ | 0.9900 | 0.60 ng mL⁻¹ | 82.30% | [73] |
| AT and metabolites | Plasma | SPE, MEPS | Gradient elution; A = ACN, B = AA (pH 4.0, 55 mM) | Acquity UPLC BEH C18 column (100 x 2.1 mm, 1.7 μm) | 0.25 | MS/MS ESI+ SRM559.5 → 440.4 | 3.0 | 0.5–100 mM | 0.03 nM | 0.08 ng mL⁻¹ | 80.34% | [74] |
| AT and metabolites | Human | PP | Gradient elution; A = 0.1% v/v glacial | ZORBAX-SB | 0.35 | MS/MS | 3.9 | 0.05–100 ng | 0.05 | 88.60–100.34% | [75] |
Table 2  Reported analytical method for the estimation of AT, its metabolites, and co-administered drugs in biological fluids using LC-MS/MS technique (Continued)

| Analyte(s)                        | Biological matrix | Sample preparation | Mode of elution; mobile phase | Stationary phase | Flow rate (mL min⁻¹) | Detection | Rₜ (min) | Calibration range | LOD | LOQ | % Recovery | Ref. |
|-----------------------------------|-------------------|--------------------|------------------------------|------------------|---------------------|-----------|----------|------------------|-----|-----|-------------|------|
| AT and metabolites                | Plasma            | PP                 | Gradient elution; A = water, B = MeOH (with 0.10% FA and 2 mM AA) | Phenyl column (100 × 2.1 mm, 3.5 μm) | 0.75–1.2 | MS/MS ESI⁺MRM59.3 → 4402 | 0.9975 | 400–1000 ng mL⁻¹ | —   | —   | 96.23%     | [76] |
| AT and amlodipine                 | Human plasma      | PP                 | Gradient elution; A = 0.1% of FA in water, B = 0.1% of FA in ACN | Eclipse XDB-C18 column (100 × 2.1 mm, 3.5 μm) | 0.75–1.2 | MS/MS ESI⁺MRM59.2 → 4402 | 111.00% | 99.65 ng mL⁻¹ | —   | —   | 96.23%     | [77] |
| Ramipril, AT, benazepril, and amlodipine | Human plasma | LLE                | Isocratic elution; 0.1% FAACN (1.5s6L, v/v) | ZORBAX SB C18 column (50 × 4.6 mm, 5 μm) | 1.0 | MS/MS ESI⁺MRM59.3 → 4402 | 96.23% | 66.18% | 67.10%     | [78] |
| AT and metabolites                | Human plasma      | SPE                | Isocratic elution; ACN0.60% v/v; AcA (70:30, v/v) | SymmetryC18 column (75 × 4.6 mm, 3.5 μm) | 0.5 | MS/MS ESI⁺MRM59.2 → 4402 | 66.18% | 0.05–0.25 ng mL⁻¹ | 0.05 | 100–68.00% | [79] |
| AT and metabolites                | Human plasma      | SPE                | Isocratic elution; ACNMeOH0.1% FA in water (50:30:20, v/v/v) | Cyro analytical column (125 × 4 mm, 5 μm) | 0.5 | MS/MS ESI⁺MRM57.31 → 397.16 | —   | 0.06ng mL⁻¹ | —   | —   | 50.00–68.00% | [80] |
| Simvastatin and AT                | Human serum       | SPE                | Gradient elution; A = ACN, B = AApH 40; 0.5 mM | Acquity UPLC BEH C18 column (100 × 2.1 mm, 1.7 μm) | 0.25 | MS/MS ESI⁺, SRM559 → 440 | 85.66% | 0.05 nM | 0.05 | —   | 85.66%     | [81] |
| AT and o-OH AT                    | Human plasma      | LLE                | Isocratic elution; ACNwater (95:5, v/v)(0.2 % FA mixed) | Sunfire C18 column (100 × 2.1 mm, 3.5 μm) | 0.5 | MS/MS ESI⁺MRM59.4 → 4405 | 85.73% | 0.10 ng mL⁻¹ | —   | —   | 85.73%     | [82] |
| AT and p-OH AT                    | Human plasma      | SPE                | Isocratic elution; 0.1% AcA in water | Genesis C18 column (50 × 2.1 mm, 4 μm) | 0.2 | MS/MS ESI⁺MRM59.3 → 4401 | 53.06% | 0.23 ng mL⁻¹ | —   | —   | 53.06%     | [83] |
| AT                                | Human plasma      | LLE                | Isocratic elution; AA (5 mM): MeOH: Methanoic acid (30:70:0.1, v/v/v) | Hypersil C18 column (150 × 4.6 mm, 5 μm) | 1.0 | MS ESI⁺SIM559.25 | 58.13% | 0.25–20 ng mL⁻¹ | —   | —   | 58.13%     | [84] |
| AT and o-OH AT                    | Human plasma      | LLE                | Isocratic elution, ACN0.1% AcA (70:30, v/v) | Atlantis d-C18 column (10 × 3 mm, 3 μm) | 0.3 | MS/MS ESI⁺MRM model559 → 440 | 91.50% | 0.10 ng mL⁻¹ | 0.10 | —   | 91.50%     | [85] |
| AT and metabolites                | Human plasma      | LLE                | Isocratic elution, 0.03% FAACN (30:70, v/v) | Symmetry C18 column (100 × 4.6 mm, 5 μm) | 1.0 | MS/MS ESI⁺MRM559 → 440 | 54.20% | 0.10 ng mL⁻¹ | 0.10 | —   | 54.20%     | [86] |
| Rosuvastatin, simvastatin, AT, and metabolites | Human plasma | LLE                | Gradient elution; A = 10 mM AF and 0.04% FA, B = ACN | Acquity UPLC BEH C18 column (100 × 2.1 mm, 1.7 μm) | 0.4 | MS/MS ESI⁺MRM59.2 → 440.3 | 97.20% | 0.25–100 ng mL⁻¹ | —   | —   | 97.20%     | [87] |
| Analyte(s)                  | Biological matrix | Sample preparation | Mode of elution; mobile phase | Stationary phase | Flow rate (mL min⁻¹) | Detection | R<sub>t</sub> (min) | Calibration range | LOD (ng mL⁻¹) | LOQ (ng mL⁻¹) | % Recovery | Ref. |
|-----------------------------|-------------------|--------------------|------------------------------|------------------|----------------------|-----------|---------------------|-----------------|--------------|---------------|------------|------|
| AT and metabolites          | Human plasma      | SPE                | Gradient elution; A = ACN+FA (1 mM) (30;70, v/v), B = ACN+FA (1 mM) (60; 40, v/v) | Omnisphere C18 column (30 x 2 mm, 3 μl) | 0.2 | MS/MS ESI<sup>+</sup> SRM559.0 → 440.2 | 6.2 | 0.2–30 ng mL⁻¹ | --- | 0.06 ng mL⁻¹ | --- | 53.00–78.00% | [88] |
| AT and metabolites          | Human serum       | LLE                | Gradient elution; A = 950 mL of water +50 mL of MeOH: 43 mL of 88% FA, B = 950 mL of ACN + 50 mL of MeOH:43 mL of 88% FA. | YMC Basic column (50 x 2 mm, 5 mm) | 03 | MS/MS ESI<sup>+</sup>MRM559.2 → 440.2 | 2.78 | 0.5–200 ng mL⁻¹ | --- | 0.50 ng mL⁻¹ | --- | 60.00–100.00% | [89] |
| AT and metabolites          | Human plasma      | LLE                | Isocratic elution; ACN:0.1% AcA (70:30, v/v) | YMC J'Sphere H80 C18 column (150 x 3.2 mm, 4 mm) | 02 | MS/MS ESI<sup>+</sup>MRM559.3 → 4402 | 4.3 | 0.250–25 ng mL⁻¹ | --- | 0.25 ng mL⁻¹ | --- | 98.40% | [90] |
| AT and metabolites          | Human plasma      | Shoot and dilute method | Gradient elution; A = 0.1% AcA, B = ACN | Acquity UPLC BEH C18 column (50 x 2 mm, 1.7 μm) | 04 | MS/MS ESI<sup>+</sup>SRM559.2 → 440.2 | 2.4 | 0.025–200 ng mL⁻¹ | --- | 0.02 ng mL⁻¹ | ---- | 97.37% | [91] |
| AT, mevastatin, pravastatin, rosuvastatin, pitavastatin, simvastatin, and lovastatin | Human urine | LLE | Gradient elution; A = 0.1% AcA, B = ACN | Kinetex C18 column (50 x 3 mm, 2.6 μm) | 035 | MS/MS ESI<sup>+</sup>MRM559.3 → 2502 | 6.4 | 1–500 ng mL⁻¹ | --- | 0.02 ng mL⁻¹ | --- | 92% | [92] |
| Bisoprolol, clopidogrel, and AT | Human plasma | PP | Isocratic elution; 0.2% FA:ACN (55:45, v/v) | Halo C18 column (50 x 2.1 mm, 2.7 μm) | 05 | MS/MS ESI<sup>+</sup>MRM559.3 → 440.3 | 3.5 | 0.5–125 ng mL⁻¹ | --- | 0.50 ng mL⁻¹ | --- | 102.40% | [93] |
| AT                          | Human plasma      | PP                 | Gradient elution; A = 0.2% (v/v) FA in water, B = ACN | Leapsil C18 column (100 x 2.1 mm, 2.7 μm) | 03 | MS/MS ESI<sup>+</sup>MRM557.0 → 4530 | 2.0 | 0.01–200 ng mL⁻¹ | --- | 0.05 ng mL⁻¹ | --- | 85.63–92.51% | [94] |
| AT and amlodipine           | Human plasma      | LLE                | Isocratic elution; ACN+ FA (pH 4.5;10 mM) (70:30, v/v) | Acquity UPLC BEH C18 column (50 x 2.1 mm, 1.7 μm) | 025 | MS/MS ESI<sup>+</sup>MRM557 → 440.2 | 0.66 | 0.05–50 ng mL⁻¹ | --- | 0.02 ng mL⁻¹ | --- | 91.30–94.00% | [95] |
| AT and metabolites          | Human plasma      | SPE                | Gradient elution; A = 0.1% AcA in water, B = ACN | Genesis C18 column (50 x 2.1 mm, 4 μm) | --- | MS/MS ESI<sup>+</sup>MRM559.4 → 440.3 | --- | r² ≥ 0.9900 | --- | --- | --- | 94.31% | [96] |
| AT                          | Human Plasma      | μ-SPE              | Gradient elution; A = AA (10 Mm), B = ACN | C18 column (100 x 3 mm, 5 μm) | 06 | MS/MS ESI<sup>+</sup>MRM559.2 → 440.1 | 4.5 | 0.2–80 ng mL⁻¹ | --- | 0.05 ng mL⁻¹ | --- | 94.60% | [97] |
| AT and niacin               | Human plasma      | LLE                | Isocratic elution; ACN: 0.1% FA (80:20, v/v) | Hypurity Advance column (50 x 4.6 mm, 5 mm) | 08 | MS/MS ESI<sup>+</sup>MRM559.0 → 4403 | 1.1 | 0.1–30 ng mL⁻¹ | --- | 0.20 ng mL⁻¹ | --- | 77.83% | [98] |
| Analyte(s)               | Biological matrix | Sample preparation | Mode of elution; mobile phase | Stationary phase | Flow rate (mL min\(^{-1}\)) | Detection | R\(_t\) (min) | Calibration range | LOD (ng mL\(^{-1}\)) | LOQ (ng mL\(^{-1}\)) | % Recovery | Ref. |
|-------------------------|-------------------|--------------------|-------------------------------|------------------|-----------------------------|------------|---------------|-------------------|------------------|---------------------|------------|------|
| AT and olmesartan       | Rat plasma        | PP                 | Isocratic elution; ACN: 0.04% glacial AcA (80:20, v/v) | Aquasil C18 column (50 x 2.1 mm, 5 μm) | 0.25 | MS/MS ESI\(^+\) MRM 559.0 → 440.0 | 1.68 | 1–1000 ng mL\(^{-1}\) | 0.15 ng mL\(^{-1}\) | 1.00 ng mL\(^{-1}\) | 85.72% [99] |
| AT and metabolites      | Human plasma      | LLE                | Isocratic elution; ACN: Water (75:25, v/v) (0.05 % v/v FA mixed) | Acquity UPLC HSS T3 column (100 x 3 mm, 1.8 μm) | 0.3 | MS/MS ESI\(^+\) MRM 559.4 → 440.1 | 2.30 | 0.2–40 ng mL\(^{-1}\) | —                | 0.20 ng mL\(^{-1}\) | 48.53% [100] |

\(^*\)The pH of the mixed solvent system.
LOD and LOQ in the reported methods have been calculated based on their signal to noise ratio, as discussed earlier; nevertheless, in some developed methods, lowest concentration of their linear calibration curve has been chosen as LOQ for analysis. The bioanalytical method developed by Zhou et al. is most sensitive than all other reported LC-MS/MS methods with the lowest LOQ of 0.036 ng mL\(^{-1}\) and the calibration curve in the range of 0.03–25 ng mL\(^{-1}\) along with intra-day and inter-day RSD of 4.02% and 5.23% respectively [69]. In more than 50% of total reported LC-MS/MS methods, LOQ is equal to or less than 0.5 ng mL\(^{-1}\) which indicates the developed LC-MS/MS methods are highly sensitive. Importantly, Novakova and co-workers have demonstrated the role of the two variables, i.e., concentration and pH of buffer solution in the mobile phase that affects the signal to noise ratio of MS/MS detector, and observed that an increase in a concentration above 5 mM significantly reduces the response of mass spectrometer and the concentrations lower than 0.5 mM were not enough to keep buffering capacity and thus had a negative impact to the response of the MS/MS detector; thus, the best response of AT and simvastatin was observed at 0.5 mM concentration of buffers. Also, AA gave better peak shapes as compared to ammonium formate (AF), and finally, AA buffer (pH 4.0; 0.5 mM) was selected as an optimized buffer for mobile phase composition [81].

Analysis of metabolites and co-administered drugs
Most of the references cited in Tables 1 and 2 also describe the simultaneous determination of AT with certain other statins [13, 20, 24, 27–29, 50, 51, 54, 56, 61, 65, 81, 87] and other co-administered drugs such as amlodipine [35, 40, 59, 64, 65, 69, 70, 77, 78, 95], ezetimibe [42, 66, 71], gemfibrozil [13, 30, 51], clopidogrel [14, 15, 41, 93], fenofibrate [26], aspirin [15, 23, 72], ramipril [64, 78], pioglitazone [17, 22], glimepiride [64, 68, 73], olmesartan [62, 98], and many other. Various methods have also been developed and validated using LC-MS/MS to quantify the metabolites of AT and are enlisted in Table 2 [54, 56–58, 60–62, 65, 67, 69, 70, 74–76, 79, 80, 82, 83, 85–91, 96, 100].

In 1999, Bullen et al. were the first to propose an LC-MS/MS method for the determination of AT and 2 of its metabolites, o-OH AT and p-OH AT in rat, dog and human plasma using a C18 column with isocratic elution of ACN and AcA (70:30, v/v) and detection in ESI’ MRM mode with transitions 559.3 → 440.2 for AT, 575.3 → 440.2 for p-OH AT, and 575.3 → 440.2 for o-OH AT [90]. Correspondingly, both the acid and lactone form of AT were simultaneously analyzed by Jemal et al. along with their 4 metabolites, i.e., o-OH AT, p-OH AT, o-OH AT-lactone, and p-OH AT-lactone in human serum in ESI’ mode with eight SRM channels using a highly sensitive and selective LC-MS/MS method [89]. However, MacWan et al. also proposed a method for quantification of AT and its 5 metabolites in human...
plasma using phenyl column [75]. Interestingly, Van pelt et al. modified the conventional LC-MS system by incorporating three valves and four columns into it for the analysis of AT and acid and lactone metabolites in human plasma to reduce the overall run time from 4.5 to 1.65 min [96].

Courlet et al. developed a UHPLC-MS/MS method for the simultaneous quantification of amlodipine, metoprolol, pravastatin, rosuvastatin, AT, α-OH AT, and p-OH AT in human plasma using their stable isotopically labeled analogs as IS. All the compounds were analyzed using ESI⁺ mode, except for pravastatin which was detected using ESI⁻ mode [65]. Vlčková et al. optimized a UHPLC−MS/MS method for selective quantification of seven statins along with their inter-converted products and metabolites in biological samples by comparing the three MS/MS detector with different specifications [55]. Likewise, Wagmann et al. proposed a highly selective method to detect seven statins and their metabolites in human blood plasma using LC-high-resolution MS/MS and applied in the therapeutic drug monitoring of these statins on 14 human plasma samples [53]. Also in 2014, eight different cardiovascular drugs were simultaneously quantified in human plasma using an APCI LC-MS/MS method by Tahboub [64]. However, an RP-HPLC-UV method was designed by Bhatia et al. for the simultaneous estimation of four cardiovascular drugs, i.e., AT, aspirin, atenolol, and losartan in tablet dosage form and plasma [23].

**Fig. 3** Product ion spectra of **a** AT, **b** α-OH AT, and **c** p-OH AT in ESI⁻ mode [66]

**Analysis in biological fluids other than blood**

Instead of analysis in common biological fluids such as plasma and serum from humans or animals, certain researchers have successfully developed liquid chromatography-based bioanalytical procedures for the quantification of AT in various other biological fluids. Silva et al. determined AT and curcumin in mouse plasma and also in the lung, brain, liver, and spleen homogenate supernatants using an HPLC-DAD assay [12]. Identically, AlKhani et al. designed a precise HPLC-UV method to quantify AT in both rat plasma and rat intestinal perfusion solution for its further application in pharmacokinetic studies [39]. The development of analytical methods for the detection of drugs and its metabolites in the urine samples generally helps to understand in vivo metabolism and clearance process, so, various methods have been developed to analyze AT in the urine samples [13, 43, 44, 47, 92]. In the year 2017, Beydokhti et al. proposed a method to simultaneously determine AT, rosuvastatin, and gemfibrozil in deionized water, wastewater, human plasma, and urine using HPLC-UV method and urine samples were prepared for analysis by diluting with 10 mL of deionized water [13]. Likewise, eight statins were simultaneously determined in human urine using a highly selective and sensitive LC-MS/MS method developed by Jang et al. in which dilute and shot approach was used for urine sample preparation [92].
Sample preparation or extraction of drug from the biological matrix

Traditionally, sample preparation is carried out by diverse techniques such as precipitation of the plasma proteins (PP), liquid-liquid extraction (LLE), and solid-phase extraction (SPE), before the final bioanalysis using liquid chromatography interfaced with UV or MS or MS/MS or capillary gas chromatography to prevent the interference of endogenous substances such as lipids, proteins, salts, acids, bases, and cells present in biological fluid with the chromatographic detection. Out of the total methods cited in Tables 1 and 2, 38% used PP for sample preparation, 33% applied LLE techniques, and 12% employed SPE technique.

Protein precipitation (PP) is the most commonly applied sample preparation technique used for the extraction of AT from biological matrix because of its rapidity, simplicity, and suitability to both hydrophilic and lipophilic analytes. PP process generally involves the addition of ACN or MeOH as precipitating agents followed by subsequent vortex and centrifugation. The % mean recoveries obtain from PP are quite significant. Acidification of the solvent has been generally employed in many PP methodologies to extract AT because the addition of acids such as trichloroacetic acid (TCA) or formic acid (FA) or AcA in the organic solvent enhanced the precipitation process due to changes in the pH [15, 25, 33, 35, 40, 65, 75, 77, 93]. Also, ice-cold extraction solvents have been used in many procedures to prevent degradation and achieve high purification of samples [15, 25, 34, 40, 46, 99]. Mathur and Devi used 10% perchloric acid as a precipitating agent along with a mixture of K₂CO₃ (2.5 M) and KOH (6 M) to maintain pH between 6.0 and 6.5 [48].

Various bioanalytical methods used LLE strategy for the sample pre-treatment of AT before the final analysis by using ethyl acetate, methyl-tertiary butyl ether, dichloromethane, or diethyl ether as organic extraction solvents. Instead of the single solvent procedure, various methods have also used a combination of different solvents [17, 27, 53, 54, 69, 85, 86] or various buffering agents such as FA [17, 60], AA [20] and phosphate buffer [33, 70–72, 85] for the extraction of AT using LLE method. Also, the addition of buffering agents to the extraction solvent has improved the recovery of analyte from biological matrices. Bullen et al. used NaOH as a buffering agent to boost the extraction of AT from the rat, dog, and human plasma [90]. Despite its few disadvantages such as time-consuming, use of toxic, expensive, and environmentally unfriendly organic solvents [18] and less selectivity toward hydrophilic drugs and metabolites [103], LLE is still extensively employed as a sample preparation technique.

Because of its laborious multistep procedure including column conditioning, sample loading, washing, and elution, followed by evaporation of the eluent, only 12% of the total reported methods adopted SPE approaches for the extraction of AT from biological matrices. Different types of reverse phase SPE cartridges or columns such as HLB or C18 SPE cartridges have been used in SPE as a stationary phase. Moreover, ACN and MeOH have been commonly employed as a solvent for column conditioning, washing, and elution along with some acid, base, or buffers to facilitate elution. SPE isolates analyte more effectively than LLE but not widely employed. Apart from its tedious procedures, cartridges used in SPE are also too expensive, and the plugging of the cartridge is also a major concern in this extraction procedure. Interestingly, Partani et al. carried out their whole SPE sample preparation process in an ice-cold water bath (excluding vortex mixing, SPE, and drying) and under low light conditions to prevent the degradation of the analyte by the temperature and light [67].

Besides conventional sample preparation approaches, many researchers used modified and novel extraction procedures to isolate AT from biological matrices. Both Hassan et al. and Yang et al. employed a novel Salting-out assisted liquid-liquid extraction (SALLE) technique for the extraction of AT from human serum and human plasma respectively using ACN salted with AA and magnesium chloride as a water-miscible solvent [18, 62]. Interestingly, this fast sample pre-treatment procedure shortens the chromatographic run time of AT. Martins et al. utilized dispersive liquid-liquid micro-extraction (DLLME) as a novel extraction method for the isolation of AT from biological matrices and compare it with the conventional SPE method [24]. A further modification in the DLLME technique with solidification in the prepared floating organic droplets has been made by Taheri et al. using a low-density solvent (Undecanol), which floats and solidifies at the top of the extraction vial during the extracted phase and separates the analyte easily [16]. Furthermore, Farajzadeh et al. used sugar cubes as a disperser base instead of a disperser solvent in the DLLME procedure to extract AT from human serum [38]. Notably, Beydokiti et al. resolved the problem of lack of sample clean-up by using tandem air-agitated LLE based on solidification of floating organic droplets (TAALLME-SFO) technique for the extraction of AT from a biological matrix. However, the use of chlorinated solvents is also a major drawback of this method [50]. Interestingly, instead of two-phase liquid microextraction, in 2009, Farahani et al. designed a novel three-phase liquid microextraction process (LLLME) in droplet-based mode to separate the analyte from complex biological matrix before HPLC assay [31].
Rukthong et al. utilized a simple, sensitive, and rapid solid-phase microextraction (SPME) technique to extract AT from human plasma using an RP-C18 SPE sorbent material which is packed in a 100-μL pipette tip to eliminates the clogging problem [97]. Because of comparative high sorption capacity and high selectivity for analytes, many researchers employed magnetic nanoparticles (MNPs) as sorbents instead of conventional SPE sorbent in the extraction of AT from biological matrices and the extraction technique involving MNP is termed as magnetic solid-phase extraction (MSPE). Tekkeli et al. used graphene nanosheets decorated with Fe₃O₄ nanoparticles as a magnetic sorbent for the extraction of AT from human plasma along with ACN as an extraction solvent [37]. Similarly in another study, Khoshhesab et al. used an ultrasound-assisted MSPE technique using sodium dodecyl sulfate-coated Fe₃O₄ MNP as a sorbent for the extraction and found it comparatively easy and fast while comparing with conventional LLE and DLLME methods [44]. Dastkhoon et al. in 2017 developed dispersive micro solid-phase extraction (Dµ-SPE) approach as a novel modification in the SPE technique for extraction of AT from human plasma and urine using Cu@SnS/SnO₂ nanoparticles loaded on activated carbon as a sorbent for separation of AT from matrices [43]. Interestingly, a combined magnetic-dispersive SPE (MD-SPE) approach was designed by Gholami and Ahmadi for the extraction of AT from human serum using polypyrrole-Fe₃O₄ MNP as sorbent [49]. Notably, Azadi and Ahmadi further used magnetic dispersive micro solid-phase extraction (MDµ-SPE) technique for the extraction of AT and valsartan from human serum and urine using CMC-coated Fe₃O₄ MNP [47]. In the same way, Beydokhti et al. developed a novel extraction technique by the combining magnetic dispersive micro SPE process and supra-molecular solvent-based microextraction process (MDµ-SPE–SSME) to extract AT, rosuvastatin, and gemfibrozil from human plasma and urine sample with the help of layered double hydroxide-coated Fe₃O₄. Also, in comparison with the conventional SPE technique, MDµ-SPE–SSME reduces the overall extraction time and eliminates the elution step [13]. Interestingly, Vlčková et al. developed microextraction by packed sorbent (MEPS) technique to extract AT and its metabolites from biological samples using a gas-tight syringe as an extraction device [56, 74]. Briefly, MEPS is a novel and miniature version SPE technique, and in comparison with the conventional SPE methods, the MEPS technique is quite simpler and time-saving and requires a lesser amount of sample. Moreover, the MEPS technique has good recovery in a short time with a lesser volume of samples.

Conclusion
Analysis of AT in the biological fluid is quite useful for pharmacokinetic studies, therapeutic drug monitoring, and drug-drug interaction studies. Numerous developed bio-analytical methods that are useful for quantitation of AT either alone or with its metabolites or co-administered drugs in plasma, serum, or urine are herein summarized and discussed. Due to advancement in technology, many new LC methods have been developed in the last decade with high sensitivity and accuracy. However, LC-MS/MS technique is more sensitive, selective, and precise as compared to the HPLC-UV technique for the quantification of AT. Also, various extraction techniques used to extract AT from biological matrices are discussed herein. Indeed, PP is the most commonly applied technique for sample preparation, followed by LLE and SPE, yet numerous advance methods have been developed such as SALLE, DLLME, and MEPS for the extraction of AT from biological fluids, to get high recovery. Thus, this review can be used as an informative tool to develop and optimize certain new LC methods for quantification of AT in biological matrices.

Abbreviations
AA: Ammonium acetate; AcA: Acetic acid; ACN: Acetonitrile; AF: Ammonium formate; APCI: Atmospheric pressure chemical ionization; AT: Atorvastatin; Dµ-SPE: Dispersive micro solid-phase extraction; DAD: Diode array detector; DLLME: Dispersive liquid-liquid micro-extraction; ESI⁺: Positive electrospray ionization; ESI⁻: Negative electrospray ionization; FA: Formic acid; LLE: Liquid-liquid extraction; LLLME: Liquid-liquid-liquid microextraction; LLME: Liquid-liquid microextraction; LOD: Limit of detection; LOQ: Limit of quantification; MSPE: Magnetic solid-phase extraction; MDµ-SPE: Magnetic dispersive micro solid-phase extraction; MeOH: Methanol; MEPS: Microextraction by packed sorbent; MRM: Multiple reaction monitoring; o-OH AT: Ortho-hydroxy Atorvastatin; PDA: Photodiode array detector; p-OH AT: Ortho-hydroxy Atorvastatin; PP: Protein precipitation; Rₜ: Retention time; r²: Regression coefficient; SALLE: Salting-out assisted liquid-liquid extraction; SIM: Selected ion monitoring; SPE: Solid-phase extraction; SPME: Solid-phase microextraction; SRM: Selected reaction monitoring; TCA: Trichloroacetic acid; UPLC: Ultra performance liquid chromatography

Acknowledgements
Not applicable

Authors’ contributions
KW: Investigation, Methodology, Writing-Original Draft, Conceptualization. ACR: Validation, Supervision. All authors have read and approved the manuscript.

Funding
This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
Data and materials are available upon request

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable
Competing interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Received: 23 July 2020 Accepted: 29 November 2020
Published online: 07 January 2021

References

1. Mäger DR (2016) Statins: and the unexpected. Home Healthc Now 34:388–393

2. Kokilambigai KS, Seetharaman R, Lakshmi KS (2017) Critical review on the application to elucidate pharmacokinetic behaviour after oral administration to rats. Int J Pharm Sci Res 4:3839–3844

3. Cheng X, Liao YH, Zhang J, Li B, Ge H, Yuan J, Wang M, Lu B, Liu Y, Cheng Y (2005) Effects of atorvastatin on Th polarization in patients with acute myocardial infarction. Eur J Heart Fail 7:1099–1104

4. Tousoulis D, Antoniades C, Katsi V, Bosnakou E, Kotsopoulos M, Tsiosufis C, Stefanidis C (2006) The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. Int J Cardiol 109:48–52

5. Newman C, Tsai J, Sarek M, Luo D, Gibson E (2006) Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97:61–67

6. Silva J, Basso J, Sousa J, Fortuna A, Vitorino C (2019) Development and full validation of an HPLC methodology to quantify atorvastatin and curcumin after their intranasal co delivery to mice. Biomed Chromatogr 33:1–11

7. Arghavan-Beydokhti S, Rajabi M, Asghari A (2017) Combination of magnetic dispersive micro solid-phase extraction and supramolecular solvent-based microextraction followed by high-performance liquid chromatography for determination of trace amounts of cholesterol-lowering drugs in complicated matrices. Anal Bioanal Chem 409:4395–4407

8. Nagavi JB, Ghupadaya B (2015) Development and validation of bioanalytical RP-ultra fast liquid chromatographic method for simultaneous estimation of clopidogrel and rosuvastatin in human plasma. Int J Curr Pharm Res 6:219–225

9. Porwal PK, Akhalaque A, Chhajed SS, Chatpalliwar VA (2013) Determination of atorvastatin and valsartan in human plasma by reversed-phase high performance liquid chromatography-UV detection. Arab J Chem 7:87–90

10. Hassan J, Bahrami SH (2014) Determination of atorvastatin in human serum by salting out assisted solvent extraction and reversed-phase high-performance liquid chromatography-UV detection. Arab J Chem 7:87–90

11. Hu L, Song W, Zhang H, Gu D (2013) HPLC-UV method development for atorvastatin calcium micro-emulsion determination in rat plasma and its application to elucidate pharmacokinetic behaviour after oral administration to rats. Int J Pharm Sci Res 4:3839–3844
49. Gholami SG, Ahmadi S (2018) Polypyrrole-modified magnetic nanoparticles for simultaneous determination of atorvastatin and ezetimibe in human plasma by using PDA detector. Adv Pharm Bull 5:385–391

50. Sultana N, Arayne MS, Naveed S (2011) Simultaneous determination of atorvastatin and ezetimibe in rat plasma by liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites, o-hydroxy atorvastatin and p-hydroxy atorvastatin, in stabilized plasma using liquid chromatography coupled with tandem mass spectrometry. J Liq Chromatogr Rel Technol 38:1585–1592

51. Arghavani-Beydokhti S, Asghari A, Bazregar M, Rajabi M (2016) Development of a tandem air-agitated liquid microextraction technique based on novel sorbent for dispersive micro solid phase extraction of atorvastatin in human plasma and urine samples. J Chromatogr A 1430:93582–93589

52. Courlet P, Spaggiari D, Desfontaine V, Cavassini M, Alves Saldanha S, Buclin T, Marcolini C, Gajka C, Decosterd LA (2019) UHPLC-MS/MS assay for determination of cholesterol-lowering drugs in complicated matrices. J Sep Sci 38:1026–1034

53. Talele GS, Porwal PK (2015) Development of validated bioanalytical HPLC method for quantification of atorvastatin in rat plasma and intestinal perfusion solution. Int J Pharm Sci Res 38:70–74

54. Vlčková H, Svoboda P, Nováková L (2011) Microextraction by packed sorbent as sample preparation step for simultaneous determination of atorvastatin and glimepiride in human plasma and its application in a bioequivalence study. J Pharm Biomed Anal 51:333–349

55. Vlčková H, Solichová D, Bláha M, Solich P, Nováková L (2011) Simultaneous determination of ezetimibe and atorvastatin in healthy male volunteers by LC-MS. Pharm Chem Sci 21:167–174

56. Vlčková H, Solichová D, Bláha M, Solich P, Nováková L (2011) Microextraction by packed sorbent as sample preparation step for simultaneous determination of atorvastatin and ezetimibe in human plasma by using PDA detector. Adv Pharm Bull 5:385–391

57. Crevar-Sakač M, Vujčić Z, Vujčić Z, Marković B, Vasičević D (2016) LC-MS/MS method for quantification of atorvastatin, o-hydroxyatorvastatin, p-hydroxyatorvastatin, and atorvastatin lactone in rat plasma. Acta Chromatogr 28:281–298

58. Chiman R, Kumar D, Kumar B, Pandey BL (2016) Quantitative determination of atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy atorvastatin in human plasma using rosuvastatin as internal standard by LC-MS / MS. Int J Pharm Sci Chem 4:487–500

59. Danafar H, Hamidi M (2015) Pharmacokinetics and bioequivalence study of amloidine and atorvastatin in healthy male volunteers by LC-MS. Pharm Chem Sci 21:167–174

60. Bayya V, Mukula A, Sanka K, Bora NS, Chaganty S (2015) Rapid, selective, and rugged method development and validation of atorvastatin and its active metabolites, o-hydroxy atorvastatin and p-hydroxy atorvastatin, in stabilized plasma using liquid chromatography coupled with tandem mass spectrometry. J Liq Chromatogr Rel Technol 38:1585–1592

61. Wang J, Luzzum JA, Philips MA, Kitzmiller JP (2015) Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma. J Chromatogr B 983–984:18–25

62. Talele GS, Porwal PK (2015) Development of validated bioanalytical HPLC method for quantification of atorvastatin in rat plasma and intestinal perfusion solution. Int J Pharm Sci Res 38:70–74

63. Vlčková H, Solichová D, Bláha M, Solich P, Nováková L (2011) Microextraction by packed sorbent as sample preparation step for simultaneous determination of atorvastatin and ezetimibe in human plasma by using PDA detector. Adv Pharm Bull 5:385–391

64. Gholami SG, Ahmadi S (2018) Polypyrrole-modified magnetic nanoparticles for preconcentration of atorvastatin in human serum prior to its determination using high-performance liquid chromatography. Micro Nano Lett 13:1425–1430

65. Sultana N, Arayne MS, Naveed S (2011) Simultaneous determination of captopril and statins in ARZ pharmaceutical formulations by RP-HPLC. J Chin Chem Soc 57:378–383

66. Gajula R, Pilli NR, Ravi VB, Maddela R, Inamadugu JK, Polagani SR, Busa T, Marzolini C, Csajka C, Decosterd LA (2019) UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. J Chromatogr B:1125:121733

67. El-Bagary R, Elkady EF, El-Sherif ZA, Kadry AM (2014) LC-MS-MS simultaneous determination of atorvastatin and ezetimibe in human plasma. J Chromatogr Sci 52:773–780

68. Partani P, Verma SM, Gurule S, Khuroo A, Monif T (2014) Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography(-)electrospray tandem mass spectrometry. J Pharm Anal 4:26–36

69. El-Bagary R, Elkady EF, El-Sherif ZA, Kadry AM (2014) LC-MS-MS simultaneous determination of atorvastatin and ezetimibe in human plasma. J Chromatogr Sci 52:773–780

70. Polagani SR, Pilli NR, Gajula R, Gandhi V (2013) Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. J Pharm Anal 3:19–39

71. Polagani SR, Pilli NR, Gajula R, Gandhi V (2013) Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. J Pharm Anal 3:19–39

72. Abdelbary G, Nebsen M (2013) Application of a novel UPLC-MS/MS method for the simultaneous determination of atorvastatin, ortho-hydroxy atorvastatin, para-hydroxy atorvastatin in human plasma using rosuvastatin as internal standard by LC-MS / MS. Int J Pharm Sci Chem 4:487–500

73. Hotha KK, Yarramu NR, Kandibedala T, Dasari VB, Vobalaboina V (2012) Simultaneous determination of atorvastatin and lercanidipine in rat plasma by HPLC and pharmacokinetic study. J Liq Chromatogr Relat Technol 34:2420–2432

74. Bayya V, Mukula A, Sanka K, Bora NS, Chaganty S (2015) Rapid, selective, and rugged method development and validation of atorvastatin and its active metabolites, o-hydroxy atorvastatin and p-hydroxy atorvastatin, in stabilized plasma using liquid chromatography coupled with tandem mass spectrometry. J Liq Chromatogr Rel Technol 38:1585–1592

75. Arghavani-Beydokhti S, Asghari A, Bazregar M, Rajabi M (2016) Application and validation of an HPLC method for simultaneous determination of atorvastatin and ezetimibe in human plasma by using PDA detector. Adv Pharm Bull 5:385–391

76. Talele GS, Porwal PK (2015) Development of validated bioanalytical HPLC method for quantification of atorvastatin in rat plasma and intestinal perfusion solution. Int J Pharm Sci Res 38:70–74

77. Vlčková H, Solichová D, Bláha M, Solich P, Nováková L (2011) Microextraction by packed sorbent as sample preparation step for simultaneous determination of atorvastatin and ezetimibe in human plasma by using PDA detector. Adv Pharm Bull 5:385–391
atorvastatin and its metabolites in biological samples-Critical evaluation. J Pharm Biomed Anal 55:301–308
75. MacWan JS, Ionita IA, Dostalek M, Akhlaghi F (2011) Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Anal Bioanal Chem 400:423–433
76. Vetke NT, Munkhaugen J, Andersen AM, Husebye E, Bergan S (2019) A method for direct monitoring of atorvastatin adherence in cardiovascular disease prevention: Quantification of the total exposure to parent drug and major metabolites using 2-channel chromatography and tandem mass spectrometry. Ther Drug Monit 41:19–26
77. Yu Q, Hu Z-Y, Zhu F-Y, Zhu J-H, Wan L-L, Li Y, Guo C (2011) HPLC–MS–MS for the simultaneous determination of atorvastatin and amloidipine in plasma of hypertensive patients. Chromatographia 73:257–262
78. Pilli NR, Inamadugu JK, Mullangi R, Karra VK, Vaidya JR, Seshagiri Rao JVLN (2011) Simultaneous determination of atorvastatin, amloidipine, taptirip and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomed Chromatogr 25:439–440
79. Ghosh C, Jain I, Gaur S, Patel N, Upadhyay A, Chakraborty BS (2011) Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS. Drug Test Anal 3:352–362
80. Jani AJ, Dasandi B, Rathnam S, Mehta AA (2010) Liquid chromatographic–MS/MS determination of atorvastatin and metabolites in human plasma. Eurasian J Anal Chem 5:46–52
81. Nováková L, Vrálová H, Šatinský D, Sadek P, Solyhová D, Bláha M, Bláha V, Solich P (2009) Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin. J Chromatogr B 877:2093–2103
82. Guillén D, Cofán F, Ros E, Millán O, Cofán M, Rimola A, Brunet M (2009) Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 394:1687–1696
83. Liu D, Jiang J, Zhou H, Hu P (2008) Quantitative determination of atorvastatin and para-hydroxy atorvastatin in human plasma by LC-MS–MS. J Chromatogr Sci 46:862–866
84. Ma L, Dong J, Chen XJ, Wang GJ (2007) Development and validation of atorvastatin by LC–ESI–MS and application in bioequivalence research in healthy chinese volunteers. Chromatographia 65:737–741
85. Bořek-Dohalský V, Huclová J, Barrett B, Němeč B, Ulič J, Jelínek I (2006) Validated HPLC–MS–MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma - Pharmacokinetic study. J Chromatogr A 1149:20–29
86. Nirogi RVS, Vrálová H, Šatinský D, Cofán F, Ros E, Millán O, Cofán M, Rimola A, Brunet M (2009) Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 394:1687–1696
87. El-Zaikli A, Cheung LK, Wang Y, Sherman V, Chow DLS (2019) Simultaneous LC–MS/MS analysis of simvastatin, atorvastatin, rosvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery. J Pharm Biomed Anal 164:258–267
88. Hermann M, Christensen H, Reubsaett JLE (2005) Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem 382:1422–1429
89. Jemal M, Ouyang Z, Chen BC, Teitz D (1999) Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospary tandem mass spectrometry. Rapid Commun Mass Spectrom 13:1003–1015
90. Bullen WW, Miller RA, Hayes RN (1999) Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog and rat plasma. J Am Soc Mass Spectrom 10:55–66
91. Cestari RN, Rocha A, Marques MP, de Oliveira RDR, Lanchote VL (2019) Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. J Chromatogr B 1126–1127:121766
92. Jang H, Mai XL, Lee G, Ahn JH, Rhee J, Truong QK, Vinh D, Hong J, Kim KH (2018) Simultaneous determination of statins in human urine by dilute-and-shoot-liquid chromatography-mass spectrometry. Mass Spectrom Lett 995–999
93. Turner RM, Fontana V, Bayliss M, Whalley S, Santoyo Castelazo A, Pirmohamed M (2018) Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. J Pharm Biomed Anal 159:272–281
94. Xia B, Li Y, Zhang Y, Xue M, Li X, Xu P, Xie T, Chen S (2018) UHPLC-MS/MS method for determination of atorvastatin calcium in human plasma: Application to a pharmacokinetic study based on healthy volunteers with specific genotype. J Pharm Biomed Anal 160:428–435
95. Rezk MR, Badr KA (2018) Quantification of amloidipine and atorvastatin in human plasma by UPLC-MS/MS method and its application to a bioequivalence study. Biomed Chromatogr 32:e4224
96. Van Pelt CK, Corso TN, Schultz GA, Lowes S, Henion J (2001) A four-column parallel chromatography system for isocratic or gradient LC/MS analyses. Anal Chem 73:582–588
97. Rukhungo P, Sangyapin P, Kitchaiya S, Jantratid E, Sathirakul K (2013) The quantitation of atorvastatin in human plasma by solid phase micro-extraction followed by LC-MS/MS and its application to pharmacokinetics study. Songklanakarin J Sci Technol 35:41–50
98. Ravi VB, Mullangi R, Inamadugu JK, Pilli NR, Gajula R, Ponneri V (2012) Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomed Chromatogr 26:1436–1443
99. Shankar Ganesh G, Deme P, Sistla R (2014) Simultaneous determination of atorvastatin calcium and olmesartan medoxomil in rat plasma by liquid chromatography electrospray ionization tandem mass spectrometry and its application to pharmacokinetics in rats. Int J Pharm Pharm Sci 6:464–468
100. Cai L, Zheng Z, Wang X, Tang L, Mai L, He G, Lei H, Zhong S (2017) Simultaneous determination of atorvastatin and its metabolites in human plasma by UPLC-MS/MS. Anal Methods 9:1038–1045
101. Braithwaite A, Smith JF (1999) Chromatographic Methods, 5th edn. Kluwer Academic Publishers
102. Guillérime D, Nguyen DTT, Rudaz S, Veuthey JL (2007) Recent developments in liquid chromatography–Impact on qualitative and quantitative performance. J Chromatogr A 1149:20–29
103. Wong A, Xiang X, Ong P, Mitchell E, Syn N, Wee I, Kumar A, Yong W, Sethi G, Goh B, Ho P, Wang L (2018) A review on liquid chromatography-tandem mass spectrometry methods for rapid quantification of oncology drugs. Pharmaceutics 10:221

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.